<DOC>
	<DOCNO>NCT01447082</DOCNO>
	<brief_summary>The main objective observational study characterize new user quetiapine XR well new user study drug ( i.e . comparison group ) quantify risk develop newly diagnose outcomes interest new user quetiapine XR well study drug .</brief_summary>
	<brief_title>General Practice Research Database Seroquel XR Safety Study</brief_title>
	<detailed_description>Epidemiology study assess safety new slow-release form Seroquel ( quetiapine ) post-marketing phase UK .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Episodes new use ( &gt; /=1 prescription ) quetiapine XR study drug Less two year record history start marketing quetiapine XR ( cohort entry date ) If duration dose antipsychotic drug determine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>atypical</keyword>
	<keyword>antipsychotic</keyword>
	<keyword>quetiapine</keyword>
</DOC>